Biosimilars | Emerging Biosimilars | Truxima Launch Tracker | Germany | Wave 1 | 2017

In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we track German physicians’ awareness of Truxima and its uptake since its launch to understand how its entry will impact the non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and the increasingly competitive immune biologics market. Along with physicians’ awareness of, familiarity with, and perceptions of biosimilars in general and of Truxima specifically, we explore the drivers of and barriers to the uptake of biosimilars/Truxima. We examine promotional efforts, as well as prescriber and nonprescriber profiles, and compare Truxima with other available biosimilars, to better understand the dynamics of the German biosimilars market.

Questions Answered

  • Are German physicians aware of Truxima and its clinical development?
  • What are the drivers to prescribing Truxima? What is the current level of Truxima use, and how is it changing over time?
  • Has experience with Truxima changed physicians’ opinions of biosimilars?
  • Have physicians experienced pressure to prescribe Truxima to patients?
  • What promotional messages are sales representatives using to sell Truxima and MabThera?
Login to access report